- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07462767
Precision Microbiota Interventions for Senoreduction Trial (PreMIS)
Geroprotektiva precisionsmedicinska strategier för personer med hiv som använder alkohol
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a randomized, double-blind, controlled, crossover mechanistic clinical trial in people with HIV who have recent alcohol use. Participants are randomized to receive either Limosilactobacillus reuteri probiotic or blueberry extract first for 4 weeks, followed by a 6-week washout period, then crossover to the alternate intervention for 4 weeks. Each participant receives both interventions.
Both interventions are generally recognized as safe (GRAS) dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This study is not conducted under an Investigational New Drug (IND) application and does not involve FDA-regulated investigational products.
Biospecimen collection and clinical assessments are performed at baseline and Week 4 of each intervention period. The primary analysis compares within-participant changes in immune senescence markers between interventions using a crossover design framework and accounts for period and sequence effects.
Participants will be recruited from HIV clinical care programs, affiliated clinics, and community outreach efforts in the New Orleans area.
A 6-week washout period is included to minimize potential carryover effects.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: David A Welsh, MD
- Telefonnummer: 5045684634 United States
- E-post: dwelsh@lsuhsc.edu
Studieorter
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70112
- Rekrytering
- LSU Health
-
Kontakt:
- David A Welsh, MD
- Telefonnummer: 5045684634 United States
- E-post: dwelsh@lsuhsc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥40 years
- People with HIV
- Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)
Exclusion Criteria:
- Probiotic use in past 3 months
- Recent antibiotics or immunosuppressives
- Allergy to study products
- Pregnancy or breastfeeding
- Inability to comply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Sequence A: Probiotic then Blueberry Extract
Participants receive probiotic for 4 weeks, washout 6 weeks, then blueberry extract for 4 weeks. |
Administered as 8 capsules daily (4 twice daily) for 4 weeks. Each daily dose contains 1×10^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product. Administered as 8 capsules daily (4 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product. |
|
Experimentell: Sequence B: Blueberry Extract then Probiotic
Participants receive blueberry extract for 4 weeks, washout 6 weeks, then probiotic for 4 weeks. |
Administered as 8 capsules daily (4 twice daily) for 4 weeks. Each daily dose contains 1×10^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product. Administered as 8 capsules daily (4 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in circulating senescent T cell numbers
Tidsram: Time 0 to Week 4 of treatment period
|
Change in circulating CD3+CD8+CD28-CD38+ T cell count (cells/µL) during treatment period. Measured by multiparameter flow cytometry. The primary endpoint is the within-participant difference in change from baseline. |
Time 0 to Week 4 of treatment period
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in additional senescent T cell phenotypes
Tidsram: Baseline and Week 4
|
Flow cytometry-defined subsets |
Baseline and Week 4
|
|
Change in epigenetic age estimation
Tidsram: Baseline and Week 4
|
Change in DNA methylation-based age estimates using epigenetic clock analyses. |
Baseline and Week 4
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in additional senescent T cell phenotypes
Tidsram: time 0 to 4 weeks
|
Exploratory analyses of additional T cell phenotypes including assess additional senescence markers including lysosomal-β-galactosidase (GLB1), proinflammatory SASP (IL-1β, IL-2, IL17A, IL-18, TNFa, IFNg, HMBG1), proliferation (Ki67), CD27, CD57, and DNA damage (p-H2A.X) in T cells at multiple stages of maturation including naïve, effector, memory, and TEMRA. |
time 0 to 4 weeks
|
|
Microbiome and metabolite profiles
Tidsram: Baseline and Week 4
|
Stool microbiome (phylogenetic analysis and bacterial genes quantification) and metabolite analyses. |
Baseline and Week 4
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: David A Welsh, MD, LSU Health New Orleans
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Blodburna infektioner
- Urogenitala sjukdomar
- Genitala sjukdomar
- Immunsystemets sjukdomar
- Infektioner
- RNA-virusinfektioner
- Virussjukdomar
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Dricksbeteende
- Beteende
- HIV-infektioner
- Alkohol dricka
- blåbärsextrakt
Andra studie-ID-nummer
- 8883
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
De-identified individual participant data will be shared upon reasonable request following publication, subject to data use agreements.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .